Oragenics Sets 2026 Goals: Advancing ONP-002 Clinical Trials

Oragenics previewed its targeted milestones for 2026. Oragenics is advancing its lead candidate ONP-002, a novel intranasal neurosteroid, through clinical studies as the potential first and only pharmacological treatment for concussion and mild traumatic brain injury. Oragenics' CEO Janet Huffman commented, "Through successful operational, regulatory and financial execution over the past year, we achieved key strategic milestones that secured the clinical infrastructure required to enter a Phase 2 clinical trial of ONP-002 in Australia this year. We have demonstrated financial discipline and transparency in support of our clinical development program, and the Company is now well-positioned to advance ONP-002 toward meaningful value-creating milestones. We remain deeply committed to delivering a much-needed therapeutic solution for patients suffering from concussion and mTBI. Based on positive pre-clinical and Phase 1 clinical safety and efficacy data with no competition in the clinic to date, ONP-002, if approved, shows potential to become the first commercial treatment for a projected $9 billion global concussion market." 2026 Value-Driving Catalysts and Milestones Near-term Phase 2a clinical site onboarding and first patient dosing. Interim Phase 2a data in throughout 2026; final readout expected in Q4 2026. Submission of an FDA IND application for U.S. trials. Ongoing strategic partnership development. Oragenics has submitted the required regulatory and ethics approvals to proceed with its Phase 2 clinical trial. However, its planned site activation is sequenced around a broad-scale health-system consolidation in Australia that will merge five hospitals in Victoria to form Bayside Health. Huffman noted, "As a result of the hospital consolidations in Australia, the merged entity is likely to prioritize certain internal organizational and governance steps in the near term. This process has delayed final verification of our HREC approval for the Phase 2a trial, extending our clinical site onboarding and patient dosing several months beyond our prior target." Oragenics' approved Phase 2a clinical trial is a randomized, placebo-controlled study designed to evaluate 40 patients that meet enrollment criteria based on CT scans, presenting systems and emergency room or hospital admission. Patients will receive first dosing within 12 hours of concussion followed by continued treatment and evaluation for up to 30 days. The trial will assess safety and tolerability parameters through follow-up visits for nasal examinations, other physical checks and neurocognitive testing. Feasibility will be determined according to tolerability and participant compliance.